Bagsværd, Denmark, 6 February 2014 – Novo Nordisk A/S has filed its Annual Report 2013 on Form 20-F for the financial year 2013 with the US Securities and Exchange Commission (SEC), incorporating by reference parts of the Novo Nordisk A/S Annual Report 2013. The reports are available at the SEC's website, www.sec.gov as well as on novonordisk.com.
Shareholders and ADR holders may receive a hard copy of the annual reports free of charge upon request by filling out a request form on novonordisk.com or upon request to email@example.com– please state the exact mailing address and the document(s) you wish to receive.
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk employs approximately 38,000 employees in 75 countries, and markets its products in more than 180 countries. For more information, visit novonordisk.com.